Introduction {#sec1}
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths, and in 2018, 781631 deaths worldwide were attributed to HCC \[[@B1]\]. Recently, the incidence of HCC has significantly increased, with approximately 840000 new cases every year \[[@B1]\]. China is a high-risk region for HCC, with the deaths caused by HCC in this country accounting for approximately 50% of HCC-related deaths worldwide \[[@B2]\]. HCC is a fatal disease with a poor prognosis. Despite the development of diagnostic methods, early detection of HCC remains difficult \[[@B3],[@B4]\]. In most patients, HCC progresses to an advanced stage, with a 5-year survival rate of less than 20% \[[@B3]\]. Surgery and liver transplantation are regarded as the optimal treatment options, but only a small proportion of HCC patients can undergo potentially curative resection \[[@B3],[@B4]\]. In addition, the therapeutic effects of current conventional treatment (CT), such as radiotherapy and chemotherapy for advanced HCC, are still unsatisfactory \[[@B3]\]. Therefore, effective comprehensive therapeutic approaches should be developed.

Traditional Chinese medicine has been widely applied as an effective complementary medicine for cancer treatment \[[@B5],[@B6]\]. Kanglaite is an extract from Coix seeds, the main active ingredient of which is a triglyceride containing four types of fatty acids \[[@B7],[@B8]\]. Kanglaite was formally approved in 1997 by the Ministry of Health of China for the treatment of malignancies such as HCC, non-small cell lung cancer (NSCLC) and pancreatic cancer (PC) \[[@B7],[@B9],[@B10]\]. Millions of cancer patients in numerous hospitals in China have been treated with kanglaite \[[@B7]\]. Moreover, kanglaite has shown good clinical efficacy in the U.S.A. It is also the first traditional Chinese medicine preparation approved by the U.S. Food and Drug Administration (FDA) for inclusion in clinical trials \[[@B11]\]. Yang et al. \[[@B8]\] demonstrated that kanglaite can effectively reverse the multidrug resistance (MDR) of human HCC and enhance the sensitivity of tumor cells to chemotherapeutic drugs by inducing apoptosis and cell cycle arrest via the PI3K/AKT pathway. Moreover, Huang et al. \[[@B12]\]. found that kanglaite can inhibit HepG2 cell transplantation-induced tumor growth by stimulating anticancer immune responses. In addition, kanglaite can induce cancer cell apoptosis by activating proapoptotic factors, such as p53, Fas and caspase-3 \[[@B13],[@B14]\].

Several studies have indicated that CT combined with kanglaite exhibits more prominent therapeutic effects for advanced HCC than does CT alone \[[@B10]\]. In a meta-analysis comparing hepatic arterial intervention combined with kanglaite and hepatic arterial intervention alone, the former had a significantly higher overall response rate (ORR), though the outcomes discussed were not complete. In fact, overall survival (OS), the disease control rate (DCR), quality of life (QoL), clinical symptoms, immune function and safety were not considered in that analysis \[[@B10]\]. Moreover, the small sample size included may have influenced the analysis of therapeutic effects. Therefore, in the present study, we conducted an up-to-date meta-analysis to investigate the clinical efficacy and safety of CT combined with kanglaite in comparison with CT alone for the treatment of advanced HCC ([Figure 1](#F1){ref-type="fig"}) to provide a scientific basis for the design of future clinical trials.

![Work flow of the present study\
(**A**) Efficacy (**B**) Safety.](bsr-39-bsr20193319-g1){#F1}

Materials and methods {#sec2}
=====================

This systematic review and meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines and Cochrane Handbook. Ethical approval was not necessary because the present study was a meta-analysis.

Search strategy and selection criteria {#sec2-1}
--------------------------------------

Nine electronic databases, namely, PubMed, Cochrane Library, Web of Science, Embase, Medline, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journal Database (VIP) and Chinese Biological Medicine Database (CBM), were searched up to May 2019 using the key terms 'kanglaite' or 'kanglaite injection' or 'kanglaite capsule' or 'coix seed capsule' or 'coix seed injection' combined with 'hepatocellular carcinoma' or 'hepatocellular cancer' or 'hepatocellular tumor' or 'liver carcinoma' or 'liver cancer' or 'hepatocellular tumor' (Supplementary Table S1).

The inclusion criteria were as follows: (1) controlled trials with advanced HCC patients; (2) studies involving more than 30 HCC patients; (3) studies comparing the clinical outcomes of CT plus kanglaite adjuvant therapy (experimental group) with those of CT alone (control group); and (4) the CT included transcatheter arterial chemoembolization (TACE), transhepatic arterial embolization (TAE), chemotherapy, stereotactic radiotherapy (SRT), support and symptomatic treatment (SST) and targeted therapy.

The exclusion criteria were as follows: (1) patients with mixed malignancies; (2) articles without sufficient available data; and (3) noncontrast articles, case studies and review papers.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Data were independently extracted by two reviewers (Jingjing Liu and Xueni Liu) according to the above inclusion and exclusion criteria; disagreements were adjudicated by the third investigator (Chao Xu). The data extracted comprised the following items: (a) the first author's name; (b) year of publication; (c) tumor stages or Karnofsky performance score (KPS); (d) number of cases; (e) therapeutic regimens; (f) dosage of kanglaite; and (g) study parameters. To ensure the quality of the meta-analysis, the quality of the included randomized and nonrandomized controlled trials was evaluated according to the Cochrane Handbook tool \[[@B15]\] and Methodological Index for Nonrandomized Studies (MINORS, Supplementary Table S2), respectively \[[@B16]\].

Outcome definition {#sec2-3}
------------------

The clinical responses assessed included treatment efficacy, QoL, clinical symptoms, immune function and adverse events. Treatment efficacy was evaluated in terms of the OS rate, ORR and DCR. QoL was assessed using the KPS scale. The clinical symptoms of the patients included the following indicators: appetite, hepatalgia, abdominal distension, fatigue and jaundice. Immune function indicators (percentages of CD3^+^, CD4^+^, CD8^+^ and NK cells and the CD4^+^/CD8^+^ ratio) and the decrease rate of α-fetoprotein (AFP) in HCC patients were determined and compared between the kanglaite and nonkanglaite groups. Adverse events, including nausea and vomiting, hepatotoxicity, nephrotoxicity, leukopenia, thrombocytopenia gastrointestinal adverse effects, anemia, fever, myelosuppression and alopecia, were also assessed.

Statistical analysis {#sec2-4}
--------------------

Statistical analysis was performed with RevMan 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 13.0 (Stata Corp., College Station, TX, U.S.A.) software. All data are expressed as odds ratios (ORs) and 95% confidence intervals (CIs), and *P*\<0.05 indicated a significant difference. Heterogeneity among the studies was assessed by Cochran's Q test; *I^2^* \< 50% or *P*\>0.1 indicated a lack of heterogeneity among the studies \[[@B17]\]. When the level of heterogeneity was small (*I^2^* \< 50%), a fixed-effects model was applied for OR estimation; otherwise, a random-effects model was selected.

Publication bias was analyzed with Begg's and Egger's regression tests, and the results are presented in funnel plots. Pooled analysis of publication bias determined that the trim-and-fill method should be applied to coordinate the estimates from unpublished studies; the adjusted results were compared with the original pooled OR \[[@B18],[@B19]\]. Sensitivity analysis was conducted to evaluate the impacts of different therapeutic regimens, kanglaite dosages, sample sizes and research types on clinical efficacy.

Results {#sec3}
=======

Search results {#sec3-1}
--------------

In total, 1021 articles were initially identified. Of those, 758 papers were excluded because they were duplicates. After title and abstract review, 201 articles were further excluded because they were not clinical trials (*n*=138), were unrelated studies (*n*=55), or were reviews or meta-analyses (*n*=8), leaving 62 studies that were potentially relevant. After a detailed assessment of the full text articles, those without a control group (*n*=13), studies that were case reports (*n*=6), and trials with insufficient data (*n*=12) were excluded. Ultimately, 31 trials \[[@B20]\] involving 2315 advanced HCC patients were included in this analysis ([Figure 2](#F2){ref-type="fig"}).

![Study selection process for the meta-analysis\
 ](bsr-39-bsr20193319-g2){#F2}

Patient characteristics {#sec3-2}
-----------------------

All included trials were performed in different medical centers in China. In total, 1219 advanced HCC patients were treated with CT combined with kanglaite adjuvant therapy; 1096 patients were treated with CT alone. All included trials except one \[[@B27]\] clearly stated the dosage of kanglaite administered. Detailed information on the involved studies and HCC patients is shown in [Table 1](#T1){ref-type="table"}. The kanglaite used was manufactured by Zhejiang Kanglaite Pharmaceutical Co., Ltd. The Quality Standards of kanglaite in the present study were approved by the Chinese State Food and Drug Administration (SFDA) and were granted a Manufacturing Approve Number issued by Chinese SFDA (Z20040138 and Z10970091). All pharmaceutical companies involved followed the quality processing procedure outlined in Chinese Pharmacopeia.

###### Clinical information from the eligible trials in the meta-analysis

  Included studies     Tumor stage/KPS   Patients Con/Exp   Therapeutic regimen   Dosage of kanglaite            Parameter types            
  -------------------- ----------------- ------------------ --------------------- ------------------------------ -------------------------- ----------------------------
  Ao, M. (2017)        ≥60               38/38              Con+ kanglaite^1^     TACE (DDP, 5-Fu, E-ADM)        20 g/time, 1 time/day      ORR, DCR, AE
  Feng, Y.Z. (2001)    II--IV            21/11              Con+KLT^1^            TAE                            20 g/time, 1 time/day      ORR, DCR, IF
  Hu, J.B. (2003)      II--IV            25/31              Con+KLT^1^            TACE (DDP, 5-Fu, THP)          20 g/time, 1 time/day      ORR, DCR, AE, CS, AFP, QoL
  Jiang, Y.B. (2006)   I--III            51/105             Con+KLT^1^            TACE (DDP, 5-Fu, ADM)          20 g/time, 1 time/day      ORR, DCR, CS, QoL
  Li, D.J. (2009)      II--III           32/30              Con+KLT^2^            TACE (DDP, 5-Fu, ADM)          2.7 g /time, 4 times/day   OS, ORR, DCR, AE, AFP, QoL
  Li, M. (2015)        II-III            23/24              Con+KLT^1^            CT (Oxaliplatin)               20 g/time, 1 time/day      OS, ORR, DCR, IF, CS, QoL
  Li, Y. (2014)        I--IV             75/75              Con+KLT^1^            CT (Meccnu, ADM, 5-Fu)         20 g/time, 1 time/day      OS, ORR, DCR, AE, QoL
  Liang, S.M. (2006)   II-III            25/31              Con+KLT^1^            TAE                            unknown                    ORR, DCR, CS, AFP
  Lu, D.P. (2017)      Unknown           43/51              Con+KLT^1^            TACE (Oxaliplatin, 5-Fu)       20 g/time, 1 time/day      OS, ORR, DCR, QoL
  Lu, H. (2006)        I--III            24/24              Con+KLT^1^            TACE (DDP, 5-Fu, MMC)          20 g/time, 1 time/day      OS, ORR, DCR, AE, QoL
  Lv, D.Z. (2004)      II--III           38/38              Con+KLT^1^            TACE (unknown), SST            20 g/time, 1 time/day      IF, CS, QoL
  Ma, W.L. (2017)      Unknown           43/43              Con+KLT^1^            CT (FOLFOX)                    20 g/time, 1 time/day      ORR, DCR, IF
  Qin, G.Y. (1998)     Unknown           20/18              Con+KLT^1^            TACE (DDP, 5-Fu, THP)          10-20 g/time, 1 time/day   ORR, DCR, CS
  Qin, Y.T. (2001)     Unknown           42/52              Con+KLT^1^            SST                            20 g/time, 1 time/day      IF
  Shao, L. (2017)      II--III           25/25              Con+KLT^1^            SRT                            20 g/time, 1 time/day      ORR, AE, QoL
  Wang, C.H. (2001)    I--III            50/50              Con+KLT^1^            TACE (DDP, ADM, HCPT)          10 g/time, 1 time/day      ORR, DCR
  Wang, X.F. (2012)    III--IV           24/34              Con+KLT^1^            TACE (unknown) FOLFOX          10 g/time, 1 time/day      ORR, AE, QoL
  Wei, Q.C. (2009)     Unknown           24/24              Con+KLT^1^            SST                            10 g/time, 1 time/day      QoL
  Wu, D.H. (2009)      II--III           30/30              Con+KLT^1^            CT (Oxaliplatin, FUDR)         20 g/time, 1 time/day      ORR, DCR, AE, CS, QoL
  Wu, J.L. (2015)      Unknown           60/60              Con+KLT^1^            TACE (unknown)                 10 g/time, 1 time/day      ORR, DCR, QoL
  Xi, D.S. (2001)      I--III            20/20              Con+KLT^1^            CT (E-ADM, 5-Fu, HCPT, ACTD)   20 g/time, 1 time/day      ORR, DCR, AE
  Xu, J. (2018)        Unknown           54/54              Con+KLT^1^            CT (Meccnu, ADM, 5-Fu)         20 g/time, 1 time/day      ORR, DCR
  Xu, X.H. (2010)      II--III           37/38              Con+KLT^1^            CT (Capecitabine)              20 g/time, 1 time/day      OS, ORR, DCR, AE, CS
  Yang, T. (2013)      ≥60               30/60              Con+KLT^1^            TACE (DDP, 5-Fu, E-ADM)        10 g/time, 1 time/day      ORR, DCR, AE, CS, QoL
  Ye, X. (2003)        III-IV            17/19              Con+KLT^1^            TACE (DDP, 5-Fu, ADM, MMC)     20 g/time, 1 time/day      ORR, DCR, AE, CS, AFP, QoL
  Yin, R.R. (2009)     Unknown           32/40              Con+KLT^1^            TACE (unknown)                 10 g/time, 1 time/day      ORR, DCR
  Yu, Z.H. (2016)      ≥50               20/20              Con+KLT^1^            Thalidomide                    20 g/time, 1 time/day      OS, ORR, DCR, AE, QoL
  Zhang, Y. (2012)     \>50              31/31              Con+KLT^1^            SST                            10 g/time, 1 time/day      AFP, QoL
  Zhang, Y.J. (2017)   II--III           48/49              Con+KLT^1^            TACE (DDP, 5-Fu, ADM, MMC)     20 g/time, 1 time/day      ORR, DCR, AE, AFP, QoL
  Zhou, S.F. (2018)    III--IV           54/54              Con+KLT^1^            Sorafenib                      20 g/time, 1 time/day      ORR, DCR, IF
  Zhu, X.F. (2006)     I--IV             40/40              Con+KLT^1^            TACE (DDP, 5-Fu, THP)          20 g/time, 1 time/day      ORR, DCR, CS, QoL

Con, control group (CTs alone group); Exp, experimental group (CTs and kanglaite group). Abbreviations: ACTD, actinomycin D; ADM, adriamycin; AE, adverse event; CF, calcium folinate; CS, clinical symptom; DDP, cisplatin; E-ADM, epirubicin; FOLFOX, qxaliplatin+CF+5-Fu; HCPT, hydroxycamptothecin; IF, immune function; MMC, mitomycin C; ORR, overall response rate; THP, pirarubicin; 5-Fu, 5-Fluorouracil.

^1^Kanglaite injection.

^2^Kanglaite capsules.

Quality assessment {#sec3-3}
------------------

The quality assessment of the risk of bias is shown in [Figure 3](#F3){ref-type="fig"} and Supplementary Table S3. The results showed that the literature recruited in the present study was of good quality.

![Risk of bias summary: review of the authors' judgments about each risk of bias item for the included randomized controlled studies\
Each color represents a different level of bias: red indicates high risk, green indicates low risk and yellow indicates an unclear risk of bias.](bsr-39-bsr20193319-g3){#F3}

Therapeutic efficacy assessments {#sec3-4}
--------------------------------

As shown in [Figures 4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"}, pooled results showed that compared with those who underwent CT alone, patients who underwent combined therapy had significantly improved 6-, 12-, 18-, 24- and 36-month OS (6-month OS: OR = 2.85, 95% CI = 1.42--5.71, *P*=0.003; 12-month OS: OR = 2.25, 95% CI = 1.51--3.36, *P*\<0.0001; 18-month OS: OR = 3.52, 95% CI = 1.54--8.09, *P*=0.003; 24-month OS: OR = 10.96, 95% CI = 1.33--90.60, *P*=0.03; 36-month OS: OR = 2.70, 95% CI = 1.53--4.75, *P*=0.0006), ORR (OR = 2.57, 95% CI = 2.10--3.16, *P*\<0.00001) and DCR (OR = 3.10, 95% CI = 2.42--3.97, *P*\<0.00001). Fixed-effect models were applied to analyze the OR rate because of the low degree of heterogeneity.

![Comparisons of OS between control and experimental group\
Forest plot of the comparison of 6-month (**A**); 12-month (**B**); 18-month (**C**); 24-month (**D**); and 36-month (**E**), OS between the experimental and control groups. Control group, CT alone group; experimental group, CTs and kanglaite group. A fixed effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-39-bsr20193319-g4){#F4}

![Forest plot of the comparison of overall response rates between the experimental and control groups\
Control group, CTs alone group; experimental group, CTs and kanglaite group. A fixed effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-39-bsr20193319-g5){#F5}

![Forest plot of the comparison of DCRs between the experimental and control groups\
Control group, CTs alone group; experimental group, CTs and kanglaite group. A fixed effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-39-bsr20193319-g6){#F6}

Detection of AFP {#sec3-5}
----------------

Six clinical trials \[[@B22],[@B24],[@B27],[@B44],[@B47],[@B48]\] with 369 patients reported data on the AFP decrease rate between the two groups. As shown in [Figure 7](#F7){ref-type="fig"}, the AFP decrease rate was significantly lower in patients receiving the combination treatment than in those receiving the CT alone (OR = 2.74, 95% CI = 1.70--4.41, *P*\<0.0001). As no obvious heterogeneity was found among the included articles, a fixed-effects model was used to pool data.

![Forest plot of the comparison of the AFP decrease rate between the experimental and control groups\
Control group, CTs alone group; experimental group, CTs and kanglaite group. A fixed effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-39-bsr20193319-g7){#F7}

QoL assessment {#sec3-6}
--------------

Nineteen trials \[[@B23],[@B28],[@B34],[@B36],[@B42],[@B46],[@B50]\] with 1449 patients reported QoL according to the KPS scale ([Figure 8](#F8){ref-type="fig"}). According to the results, the QoL of HCC patients in the combined group was significantly better than that of patients in the control group (OR = 3.80, 95% CI = 3.01--4.80, *P*\<0.00001). A fixed-effect model was used due to the low level of heterogeneity.

![Forest plot of the comparison of QoL scores between the experimental and control groups\
Control group, CTs alone group; experimental group, CTs and kanglaite group. A fixed effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-39-bsr20193319-g8){#F8}

Assessment of clinical symptoms {#sec3-7}
-------------------------------

The clinical symptoms of HCC patients receiving combined therapy were significantly improved compared with those of patients treated with CT alone (Supplementary Figure S1, OR = 5.36, 95% CI = 3.21--8.94, *P*\<0.00001), as indicated by increased appetite and reductions in hepatalgia, abdominal distension, fatigue and jaundice (Supplementary Figure S1, appetite: OR = 5.50, 95% CI = 1.72--17.61, *P*=0.004; hepatalgia: OR = 2.95, 95% CI = 1.74--5.00, *P*\<0.0001; abdominal distension: OR = 3.52, 95% CI = 1.33--9.31, *P*=0.01; fatigue: OR = 4.60, 95% CI = 1.89--11.22, *P*=0.0008; jaundice: OR = 1.42, 95% CI = 0.41--4.95, *P*=0.59), though the improvement in jaundice was not significant.

Immune function evaluation {#sec3-8}
--------------------------

The immune status of patients between kanglaite and nonkanglaite groups was examined in six controlled studies \[[@B21],[@B25],[@B30],[@B31],[@B33],[@B49]\]. As presented in [Figure 9](#F9){ref-type="fig"}, the percentages of CD3^+^, CD4^+^ and CD8^+^ cells and the CD4^+^/CD8^+^ ratio were significantly higher in the combined treatment group than in the control group (CD3^+^: OR = 9.12, 95% CI = 6.69--11.56, *P*\<0.00001; CD4^+^: OR = 7.01, 95% CI = 4.32--9.69, *P*\<0.00001; CD8^+^: OR = 0.99, 95% CI = 0.23--1.76, *P*=0.01; CD4^+^/CD8^+^: OR = 0.33, 95% CI = 0.19--0.47, *P*\<0.00001). However, the proportions of NK (CD3^−^CD56^+^) cells did not differ significantly between the two groups (OR = 13.16, 95% CI = −3.25--29.56, *P*=0.12). The percentage of CD8^+^ cells was not heterogeneous among the studies; thus, a fixed-effect model was used to analyze the OR. Otherwise, random-effects models were used.

![Comparisons of immune function between control and experimental group\
Forest plot of the comparison of immune function (CD3^+^ (**A**); CD4^+^ (**B**); CD8^+^ (**C**); CD3^−^CD56^+^ (**D**); and CD4^+^/CD8^+^ (**E**)) between the experimental and control groups. Control group, CTs alone group; experimental group, CTs and kanglaite group.](bsr-39-bsr20193319-g9){#F9}

Assessment of adverse events {#sec3-9}
----------------------------

As shown in [Table 2](#T2){ref-type="table"} and Supplementary Figure S2, compared with patients treated with CT alone, those treated with kanglaite and CT displayed lower incidence rates of nausea and vomiting \[[@B24],[@B26],[@B34],[@B36],[@B42],[@B48],[@B50]\], hepatotoxicity \[[@B20],[@B22],[@B24],[@B34],[@B36],[@B44],[@B50]\] leukopenia \[[@B22],[@B34],[@B44],[@B48],[@B50]\], thrombocytopenia \[[@B22],[@B34],[@B49],[@B50]\], gastrointestinal side effects \[[@B20],[@B25],[@B29],[@B43],[@B44],[@B46]\] and fever \[[@B24],[@B44],[@B48]\] (nausea and vomiting: OR = 0.62, 95% CI = 0.39--0.97, *P*=0.04; hepatotoxicity: OR = 0.40, 95% CI = 0.25--0.66, *P*=0.0002; leukopenia: OR = 0.28, 95% CI = 0.17--0.47, *P*\<0.00001; thrombocytopenia: OR = 0.21, 95% CI = 0.10--0.42, *P*\<0.0001; gastrointestinal side effects: OR = 0.43, 95% CI = 0.22--0.84, *P*=0.01; fever: OR = 0.37, 95% CI = 0.20--0.66, *P*=0.0009). In contrast, the incidence rates of nephrotoxicity \[[@B22],[@B44],[@B50]\], anemia \[[@B22],[@B50]\], myelosuppression \[[@B26],[@B43]\] and alopecia \[[@B26],[@B49]\] (nephrotoxicity: OR = 0.16, 95% CI = 0.01--3.56, *P*=0.25; anemia: OR = 0.75, 95% CI = 0.33--1.73, *P*=0.50; myelosuppression: OR = 0.64, 95% CI = 0.34--1.19, *P*=0.16; alopecia: OR = 0.64, 95% CI = 0.34--1.24, *P*=0.19) did not differ significantly between the two groups. Fixed-effect models were used in these analyses due to the low level of heterogeneity.

###### Comparison of adverse events between the experimental and control groups

  Adverse events                     Experimental group   Control group   Analysis method   Heterogeneity   OR     95% CI   *P*-value    
  ---------------------------------- -------------------- --------------- ----------------- --------------- ------ -------- ------------ -----------
  Nausea and vomiting                291                  281             Fixed             0               0.53   0.62     0.39--0.97   0.04
  Hepatotoxicity                     217                  201             Fixed             0               0.70   0.40     0.25--0.66   0.0002
  Nephrotoxicity                     90                   82              Fixed             ─               ─      0.16     0.01--3.56   0.25
  Leukopenia                         164                  155             Fixed             0               0.94   0.28     0.17--0.47   \<0.00001
  Thrombocytopenia                   150                  144             Fixed             0               0.79   0.21     0.10--0.42   \<0.0001
  Gastrointestinal adverse effects   185                  152             Fixed             0               0.64   0.43     0.22--0.84   0.01
  Anemia                             71                   65              Fixed             0               0.64   0.75     0.33--1.73   0.50
  Fever                              98                   97              Fixed             10              0.33   0.37     0.20--0.66   0.0009
  Myelosuppression                   135                  105             Fixed             0               0.71   0.64     0.34--1.19   0.16
  Alopecia                           129                  129             Fixed             0               0.72   0.64     0.34--1.24   0.19

Control group, CTs alone group; Experimental group, CTs and kanglaite group.

Publication bias {#sec3-10}
----------------

Publication bias was assessed visually with funnel plots. As illustrated in [Figure 10](#F10){ref-type="fig"}, the funnel plots were symmetrical for ORR and QoL but asymmetrical for DCR.

![Funnel plot of publication bias\
Funnel plot of the ORR (**A**); DCR (**B**); and QoL (**C**).](bsr-39-bsr20193319-g10){#F10}

We also assessed publication bias by Begg's and Egger's regression tests, and DCR was found to have bias (Begg = 0.059; Egger = 0.005). Conversely, no significant publication bias was found for ORR (Begg = 0.802; Egger = 0.680) or QIR (Begg = 0.675; Egger = 0.630). To determine if the bias affected the pooled risk for DCR, we conducted a trim-and-fill analysis. The adjusted OR indicated the same trend as was indicated by the result of the primary analysis (before: *P*\<0.0001, after: *P*\<0.0001), reflecting the reliability of our primary conclusions.

Sensitivity analysis {#sec3-11}
--------------------

A sensitivity analysis was conducted, and one trial \[[@B24]\] was excluded because the type of kanglaite was in capsule form in the present study. The results of this analysis were similar to those obtained from the overall analysis of the pooled trials.

To explore the sources of ORR, DCR and QoL heterogeneity, we also conducted subgroup analyses with respect to therapeutic regimen, kanglaite dosage, sample size and type of study. As shown in [Table 3](#T3){ref-type="table"}, our analysis revealed no significant differences between different dosages of kanglaite, sample sizes and types of studies. Moreover, our results showed that kanglaite increased ORR and DCR among HCC patients only when combined with TACE/CT regimens.

###### Subgroup analyses of ORR, DCR and QoL between the experimental and control groups

  Parameter   Factors at study level       Experimental group   Control group   Analysis method   Heterogeneity   OR     95% CI   *P*-value     
  ----------- ---------------------------- -------------------- --------------- ----------------- --------------- ------ -------- ------------- -----------
  ORR         **Therapeutic regimen**                                                                                                           
              kanglaite+TACE               649                  534             Fixed             0               0.95   2.49     1.91--3.25    \<0.00001
              kanglaite+CT                 284                  282             Fixed             0               0.71   2.62     1.81--3.78    \<0.00001
              kanglaite+TAE                42                   46              Fixed             0               0.69   2.88     0.71--11.78   0.14
              **Dosage of kanglaite**                                                                                                           
              200 ml/day                   751                  688             Fixed             0               0.98   2.47     1.93--3.15    \<0.00001
              100 ml/day                   244                  196             Fixed             0               0.78   3.09     2.01--4.73    \<0.00001
              **Study sample size**                                                                                                             
              \>60                         787                  687             Fixed             0               0.96   2.64     2.07--3.36    \<0.00001
              ≤60                          287                  274             Fixed             0               0.96   2.41     1.63--3.56    \<0.0001
              **Type of control trials**                                                                                                        
              RCT                          878                  772             Fixed             0               0.99   2.53     2.01--3.20    \<0.00001
              Non-RCT                      196                  189             Fixed             0               0.78   2.72     1.76--4.21    \<0.00001
  DCR         **Therapeutic regimen**                                                                                                           
              kanglaite+TACE               615                  510             Fixed             0               0.48   2.74     2.02--3.72    \<0.00001
              kanglaite+CT                 284                  282             Fixed             0               0.90   3.71     2.36--5.82    \<0.00001
              kanglaite+TAE                42                   46              Fixed             0               0.95   6.26     0.72--54.47   0.10
              **Dosage of kanglaite**                                                                                                           
              200 ml/day                   726                  663             Fixed             0               0.96   3.56     2.63--4.81    \<0.00001
              100 ml/day                   210                  172             Fixed             40              0.17   2.07     1.30--3.30    0.002
              **Study sample size**                                                                                                             
              \>60                         787                  687             Fixed             0               0.80   2.58     1.95--3.40    \<0.00001
              ≤60                          228                  225             Fixed             0               1.00   6.14     3.47--10.88   \<0.00001
              **Type of control trials**                                                                                                        
              RCT                          819                  723             Fixed             0               0.79   2.99     2.28--3.94    \<0.00001
              Non-RCT                      196                  189             Fixed             0               0.60   3.59     2.01--6.40    \<0.0001
  QoL         **Therapeutic regimen**                                                                                                           
              kanglaite+TACE               510                  407             Fixed             0               0.99   3.81     2.83--5.14    \<0.00001
              kanglaite+CT                 167                  165             Fixed             0               0.82   3.88     2.43--6.20    \<0.00001
              kanglaite+SST                55                   55              Fixed             0               0.85   4.89     1.89--12.61   0.001
              **Dosage of kanglaite**                                                                                                           
              200 ml/day                   538                  471             Fixed             0               0.99   3.62     2.75--4.78    \<0.00001
              100 ml/day                   209                  169             Fixed             0               1.00   4.48     2.80--7.17    \<0.00001
              **Study sample size**                                                                                                             
              \>60                         577                  485             Fixed             0               0.99   3.89     2.94--5.14    \<0.00001
              ≤60                          200                  187             Fixed             0               0.96   3.58     2.33--5.50    \<0.00001
              **Type of control trials**                                                                                                        
              RCT                          669                  565             Fixed             0               1.00   3.63     2.81--4.68    \<0.00001
              Non-RCT                      108                  107             Fixed             0               0.98   4.88     2.71--8.76    \<0.00001

Control group, CTs alone group; Experimental group, CTs and kanglaite group. Abbreviation: kanglaite, Kanglaite.

Discussion {#sec4}
==========

The disadvantages of current CT for malignancies, such as drug resistance and toxic side effects, are a substantial burden for cancer patients \[[@B3],[@B5]\]. Clinicians have been exploring complementary and alternative treatments to improve patients' survival time, QoL and immune function and to reduce side effects caused by radiochemotherapy \[[@B3],[@B5],[@B10]\]. Kanglaite, a type of traditional Chinese medicine, has been clinically applied as an adjuvant therapy for decades \[[@B12],[@B51]\]. Many studies have reported that the addition of kanglaite may be beneficial for HCC patients \[[@B14]\]. Although statistical analyses of the published literature have been performed, the exact therapeutic effects have not been systematically investigated. In this analysis, we conducted a wide-ranging online search with strict inclusion and exclusion criteria to provide clear and systematic conclusions.

The meta-analysis was performed with 27 articles \[[@B20],[@B31],[@B32],[@B34],[@B38],[@B48]\] to evaluate the clinical efficacy of the addition of kanglaite to CT. Our analysis found that compared with CT alone, the combination of kanglaite and CT significantly improved survival time at 6, 12, 18, 24 and 36 months (*P*\<0.05), suggesting that the addition of kanglaite to CT might prolong the survival time of HCC patients with advanced disease. The analysis considered ORR, DCR, QoL and clinical symptoms, all of which showed significant improvements in the combined group compared with the control group. Moreover, AFP is commonly used to predict the recurrence, metastasis and prognosis of HCC after comprehensive treatments \[[@B52],[@B53]\], and our analysis showed that AFP was clearly reduced after treatment with the combination of CT and kanglaite. All these results indicate that using kanglaite might enhance the curative effects of CT for advanced HCC.

The immunosuppressed status of cancer patients has been reported, and immune system reconstruction is a critical approach for effectively treating malignancies. Our analysis showed that the percentages of CD3^+^, CD4^+^ and CD8^+^ cells and the CD4^+^/CD8^+^ ratio were significantly increased when kanglaite was administered to HCC patients, indicating that the immune function of HCC patients was improved by kanglaite-mediated therapy.

The meta-analysis evaluated the incidence rates of side effects after therapy, clearly showing reductions in nausea and vomiting, hepatotoxicity, leukopenia, thrombocytopenia, gastrointestinal side effects and fever (*P*\<0.05) in the combined group compared with the control group. Therefore, kanglaite is a safe auxiliary antitumor medicine for advanced HCC and can effectively alleviate some of the adverse events associated with CT.

This analysis of therapeutic effects may have been influenced by several factors. In our study, no differences were found between different dosages of kanglaite, sample sizes and research types. Moreover, the results of subgroup analyses indicated that kanglaite increased HCC patient ORR and DCR only when combined with TACE/CT regimens. Nonetheless, recent studies on the impacts of these factors on the curative effect of kanglaite adjuvant therapy remain insufficient, and further investigations should be performed.

There are some limitations in our analysis. First, as an important Chinese herbal preparation, kanglaite is mainly used in China, which may result in unavoidable regional bias and subsequently influence the clinical application of kanglaite worldwide. Currently, four clinical trials in the U.S.A. in which malignancies are being treated by kanglaite in conjunction with conventional regimens have been registered on ClinicalTrials.gov (one for prostate cancer, NCT01483586; one for NSCLC, NCT01640730; one for PC, NCT00733850; and one for refractory solid tumors, NCT00031031). Schwartzberg et al. (NCT00733850) \[[@B7]\] reported that compared with gemcitabine alone, kanglaite injection combined with gemcitabine significantly improved the progression-free survival, median OS and QoL of PC patients. Regardless, to date, no trial meeting our inclusion criteria has been published outside China. We will continue to pay close attention to global studies in further analyses. Second, confounding factors such as smoking and alcohol history may have an impact on the efficacy of kanglaite-mediated therapy. However, our data were extracted from publications where this information was not sufficiently provided. Therefore, based on currently available literature, there are insufficient data to perform a statistical analysis to evaluate correlations. We will focus on this concern in future studies. Third, as the sources of our data were published articles instead of raw records from clinical trials, analytical bias may exist. Finally, significant heterogeneity among the included trials was found in some cases, which may be due to the different ages of the HCC patients, tumor stages and durations of treatment. However, based on the currently available literature, there are insufficient data to perform more statistical analyses to evaluate these correlations.

Conclusions {#sec5}
===========

In conclusion, the findings of this meta-analysis indicate that kanglaite combined with CT is effective in treating advanced HCC. The clinical application of kanglaite not only clearly enhances the therapeutic effects of CT but also effectively improves the QoL and immune function of HCC patients. However, the low quality of some of the included publications increases the risk of bias, which to some extent affects the reliability of the research. The clinical efficacy of kanglaite-mediated adjuvant therapy for advanced HCC still needs to be verified in methodologically rigorous trials.
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AFP

:   α-fetoprotein

CI

:   confidence interval

CNKI

:   China National Knowledge Infrastructure

CT

:   conventional treatment

DCR

:   disease control rate

HCC

:   hepatocellular carcinoma

KPS

:   Karnofsky performance score

NSCLC

:   non-small cell lung cancer

OR

:   odds ratio

ORR

:   overall response rate

OS

:   overall survival

PC

:   pancreatic cancer

QoL

:   quality of life

SFDA

:   Chinese State Food and Drug Administration

TACE

:   transcatheter arterial chemoembolization

TAE

:   transhepatic arterial embolization
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